- Home
- SAVA vs GSIW Comparison
SAVA vs GSIW Comparison
Compare SAVA & GSIW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SAVA
- GSIW
- Stock Information
- Founded
- SAVA 1998
- GSIW 2016
- Country
- SAVA United States
- GSIW Hong Kong
- Employees
- SAVA N/A
- GSIW N/A
- Industry
- SAVA Biotechnology: Pharmaceutical Preparations
- GSIW
- Sector
- SAVA Health Care
- GSIW
- Exchange
- SAVA Nasdaq
- GSIW Nasdaq
- Market Cap
- SAVA 70.5M
- GSIW 57.7M
- IPO Year
- SAVA N/A
- GSIW 2023
- Fundamental
- Price
- SAVA $2.35
- GSIW $0.13
- Analyst Decision
- SAVA Buy
- GSIW
- Analyst Count
- SAVA 2
- GSIW 0
- Target Price
- SAVA $54.50
- GSIW N/A
- AVG Volume (30 Days)
- SAVA 1.2M
- GSIW 31.5M
- Earning Date
- SAVA 08-07-2025
- GSIW 01-01-0001
- Dividend Yield
- SAVA N/A
- GSIW N/A
- EPS Growth
- SAVA N/A
- GSIW N/A
- EPS
- SAVA N/A
- GSIW N/A
- Revenue
- SAVA N/A
- GSIW $1,313,795.00
- Revenue This Year
- SAVA N/A
- GSIW N/A
- Revenue Next Year
- SAVA N/A
- GSIW N/A
- P/E Ratio
- SAVA N/A
- GSIW N/A
- Revenue Growth
- SAVA N/A
- GSIW N/A
- 52 Week Low
- SAVA $1.15
- GSIW $0.10
- 52 Week High
- SAVA $42.20
- GSIW $12.30
- Technical
- Relative Strength Index (RSI)
- SAVA 56.89
- GSIW 18.52
- Support Level
- SAVA $2.11
- GSIW $0.10
- Resistance Level
- SAVA $2.72
- GSIW $0.34
- Average True Range (ATR)
- SAVA 0.16
- GSIW 0.23
- MACD
- SAVA 0.04
- GSIW -0.20
- Stochastic Oscillator
- SAVA 52.56
- GSIW 1.93
About SAVA Cassava Sciences Inc.
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is currently conducting two randomized placebo-controlled Phase 3 clinical trials of oral simufilam in patients with Alzheimer's disease dementia. It has one business segment: the development of novel drugs and diagnostics.
About GSIW Garden Stage Limited
Garden Stage Ltd is a Hong Kong-based financial services provider principally engaged in the provision of placing and underwriting services; securities dealing and brokerage services; and asset management services. Its business is carried out through its wholly owned Operating Subsidiaries: a) I Win Securities, which is licensed to conduct Type 1 (dealing in securities) regulated activities under the SFO in Hong Kong, and b) I Win Asset Management, which is licensed to conduct Type 4 (advising on securities) and Type 9 (asset management) regulated activities under the SFO in Hong Kong.